Aptamers

2022 Activity indicators

  • 4 competitive public projects - ISCIII, MINECO/MICINN
  • 1 private led project
  • 1 private competitive project led
  • 2 competitive HR contracts.
  • 8 publications
  • IF: 50,994
  • D1 publications: 1 (12,5 %)
  • Q1 publications: 6 (72 %)
  • 1 supervised doctoral thesis read
  • Evaluators of projects in national institutions: 3 PIs.
  • Evaluators of projects in European institutions: 1 PI.
  • Members of editorial committees: 1 PI.
  • 7 active Patent families with priority patent:
    • P201430955 "TLR4-specific aptamers and their potential use for the treatment of stroke". Entry into national phases in 15 countries
    • P201930524 "FPR2 receptor agonist aptamers" with PCT/ES2020/070378 and national phase entry in the USA.
    • EP 18 382 888.8 "Aptamers specific against human MNK1 protein and their use in MNK1 detection method and as MNK1 inhibitor" with PCT/EP2019/083547 and national phase entry in Europe and USA.
    • EP17382610 "MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells" with PCTEP2018/06815 extended in USA and Europe.
    • EP21382710.8 "Aptamers against the hepatitis c virus core protein" with PCT/EP2022/071188.
    • EP22382616.5 "DNA aptamer conjugates recognizing and degrading coronavirus proteins".
    • EP22382617.3 "DNA aptamer conjugates recognizing and degrading coronavirus proteins".
  • 2 technology licensing agreements signed in the year.

Milestones

  1. Establishment of multiple collaborations related to aptamer technology.
  2. Successful award of new competitive public grants: 1) AES22 Personalised Medicine project "Preclinical development of the aptamer apMNKQQ2 targeting MNK1 in gastrointestinal cancer" (PMPTA22/00113); 2) AES22 equipment acquisition grant "Acquisition of equipment for non-invasive fluorescence and proteomic characterisation of tissues" (IFEQ22/00111); 3) first European project in the EU-LAC call of Horzonte Europa entitled "Aptamer-based strategies to create novel biotechnological tools against Arboviruses (ABSarbo)".
  3. Defence of a doctoral thesis related to the therapeutic use of aptamers by members of the group: "Selection and characterisation of aptamers against histone acetyltransferase 1 (HAT1). Potential therapeutic use in lung cancer".
  4. Completion of the phase IIa clinical trial of the APTOLL aptamer entitled "First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers", developed by the IRYCIS aptamer group in collaboration with Aptus Biotech, with very promising results.
  5. Consolidation of the UCS of Aptamers, constituted from the research group and which provides aptamer selection services to IRYCIS and external groups.

Bibliometrics

  Articles Accum. FI Mean FI Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2018 6 25,6 4,27 4 67 2 33
2019 0 0,00 0,00 0 0 0 0
2020 6 24,41 4,88 5 83 1 17
2021 6 38,28 6,38 6 100 1 17
2022 8 50,994 6,34 6 75 1 12,5
  26 139,30 4,37 21 65 5 16

* Only original articles, editorials, guidelines and reviews

Networks and alliances